Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Journal of Biological Chemistry, 266(7), 4029-4032
This research provides a theoretical basis for the development of iron-based nanoparticles as a novel therapeutic agent for ovarian cancer and offers new hope for clinical treatment of ovarian cancer patients
By advancing through several generations of inhibitors, a series of inhibitors of TGR was obtained (Fig
Cools, J
For example, a 10 mg vial mixed with 2 mL of BAC water is 5 mg/mL
US$ 20.01
US$ 23.12
US$ 28.20
:max_bytes(150000):strip_icc()/VWH-GettyImages-2276706586.jpg-4e49ad1f948143ed99767b89bf0289d7.jpg)
